文献速递皮肤肿瘤

单疗程5%氟尿嘧啶乳膏化学预防基底细胞癌与鳞状细胞癌:一项随机临床试验

Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial.
PubMed 文献 · JAMA Dermatol · 2018-01-01

该随机双盲安慰剂对照试验纳入932例有至少2次角化细胞癌病史的退伍军人,面部及耳部外用5%氟尿嘧啶或赋形剂对照乳膏每日两次2至4周。第一年氟尿嘧啶组鳞状细胞癌风险较对照组降低75%(95%CI 35%-91%,P=0.002),基底细胞癌风险降低11%未达统计学显著。

要点

  • 面部及耳部单疗程5%氟尿嘧啶使第一年鳞状细胞癌风险降低75%(95%CI 35%-91%,P=0.002)。
  • 第一年基底细胞癌风险降低11%未达统计学显著(95%CI 降低39%至增加31%)。
  • 整个研究期间两组首次角化细胞癌、基底细胞癌或鳞状细胞癌时间无差异。

核心结论

  • 面部及耳部常规疗程氟尿嘧啶可大幅减少第一年因鳞状细胞癌手术,而未显著影响相应基底细胞癌风险。

研究设计与样本

  • 退伍军人事务部角化细胞癌化学预防试验为随机双盲安慰剂对照试验,2009年5月至2011年9月从12个退伍军人事务医疗中心招募,随访至2013年6月30日。
  • 纳入932例过去5年内有至少2次角化细胞癌病史的退伍军人,几乎均为白人男性,中位年龄70岁。
  • 随机分配至5%氟尿嘧啶组(n=468)或赋形剂对照乳膏组(n=464),面部及耳部每日两次涂抹2至4周。

主要发现

  • 932例参与者中916例男性(98%)、926例白人(99%),中位年龄70岁;4年内299例发生基底细胞癌终点(第一年95例),108例发生鳞状细胞癌终点(第一年25例),中位随访2.8年。
  • 整个研究期间两组首次角化细胞癌、基底细胞癌或鳞状细胞癌时间无差异。
  • 第一年氟尿嘧啶组5例(1%)发生鳞状细胞癌 vs 对照组20例(4%),风险降低75%(95%CI 35%-91%,P=0.002)。
  • 第一年基底细胞癌风险降低11%(氟尿嘧啶组45例[10%] vs 对照组50例[11%])未达统计学显著(95%CI 降低39%至增加31%),对角化细胞癌风险亦无显著影响。
  • 观察到接受莫氏手术治疗的角化细胞癌减少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Keratinocyte carcinoma (ie, cutaneous basal and squamous cell carcinoma) is the most common cancer in the United States. OBJECTIVE: To determine whether topical fluorouracil could prevent surgically treated keratinocyte carcinoma. DESIGN, SETTING, AND PARTICIPANTS: The Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial was a randomized, double-blind, placebo-controlled trial of topical fluorouracil for chemoprevention of keratinocyte carcinoma. Participants were recruited from May 2009 to September 2011 from 12 Veterans Affairs medical centers and followed until June 30, 2013. Participants were veterans (n = 932) with a history of at least 2 keratinocyte carcinomas in the past 5 years; almost all were white males and the median age was 70 years. INTERVENTIONS: Application of fluorouracil, 5%, (n = 468) or vehicle control cream (n = 464) to the face and ears twice daily for 2 to 4 weeks upon randomization. MAIN OUTCOMES AND MEASURES: Surgically treated keratinocyte, basal cell, and squamous cell carcinoma risk on the face and ears in the first year after enrollment; and time to first surgically treated keratinocyte, basal cell, and squamous cell carcinoma. The a priori hypothesis was that fluorouracil would be effective in preventing these cancers. RESULTS: Of 932 participants (916 men [98%]; 926 white [99%]; median age, 70 years), 299 developed a basal cell carcinoma end point (95 in year 1) and 108 developed a squamous cell carcinoma end point (25 in year 1) over 4 years (median follow-up, 2.8 years). Over the entire study, there was no difference between treatment groups in time to first keratinocyte, basal cell, or squamous cell carcinoma. During the first year, however, 5 participants (1%) in the fluorouracil group developed a squamous cell carcinoma vs 20 (4%) in the control group, a 75% (95% CI, 35%-91%) risk reduction (P = .002). The 11% reduction in basal cell carcinoma risk during year 1 (45 [10%] in the fluorouracil group vs 50 [11%] in the control group) was not statistically significant (95% CI, 39% reduction to 31% increase), nor was there a significant effect on keratinocyte carcinoma risk. However, a reduction in keratinocyte carcinomas treated with Mohs surgery was observed. CONCLUSIONS AND RELEVANCE: A conventional course of fluorouracil to the face and ears substantially reduces surgery for squamous cell carcinoma for 1 year without significantly affecting the corresponding risk for basal cell carcinoma. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00847912.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Weinstock MA, Thwin SS, Siegel JA, et al. Chemoprevention of Basal and Squamous Cell Carcinoma With a Single Course of Fluorouracil, 5%, Cream: A Randomized Clinical Trial. JAMA Dermatol. 2018. PMID: 29299592. doi:10.1001/jamadermatol.2017.3631

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。